US pharma giant Pfizer (NYSE: PFE) and Germany’s BioNTech (Nasdaq: BNTX) will amend the clinical study evaluating the safety, tolerability, and immunogenicity of their Comirnaty COVID-19 vaccine in children six months to under five years of age.
The study will now include evaluating a third dose of 3µg at least two months after the second of the two-dose series to provide high levels of protection in this young age group.
While the study is ongoing and remains blinded, a pre-specified immunogenicity analysis was conducted on a subset of the study population one month following the second dose.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze